Breaking News, Collaborations & Alliances

Nektar and Takeda in Research Collaboration

Will explore combination cancer therapies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Nektar Therapeutics and Takeda have entered into a research collaboration to explore the combination of Nektar’s lead immuno-oncology candidate, the CD122-biased agonist NKTR-214, with five oncology compounds from Takeda’s cancer portfolio. The two companies will explore the anti-cancer activity of NKTR-214 with five different targeted mechanisms in preclinical tumor models of lymphoma, melanoma and colorectal cancer. “We look forward to collaborating with Takeda to explore ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters